FDA Initiates Class II Recall for DermaRite's KleenFoam Antimicrobial Foam Soap Over CGMP Deviation
DermaRite Industries, LLC faces an FDA Class II recall for 15,267 cartridges of KleenFoam Antimicrobial Foam Soap (Chloroxylenol 0.5%). This action stems from a CGMP deviation at its North Bergen, NJ facility, where other products were found contaminated. Procurement and regulatory teams must assess supply chain continuity and quality assurance protocols for similar products.
FDA Initiates Class II Recall for DermaRite's KleenFoam Antimicrobial Foam Soap Over CGMP Deviation
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall, identified as D-0168-2026, for DermaRite Industries, LLC’s KleenFoam Antimicrobial Foam Soap. This specific product, containing Chloroxylenol 0.5% and packaged in 34 FL OZ (1000 mL) cartridges, is manufactured at DermaRite’s facility located at 7777 West Side Avenue, North Bergen, NJ 07047. The recall, voluntarily initiated by DermaRite Industries on August 27, 2025, impacts all lots with an expiry date on or before August 2027, totaling 15,267 cartridges distributed nationwide across the USA. For procurement directors and supply chain VPs, this signifies an immediate need to verify inventory of this specific product and assess potential shortages, particularly if DermaRite is a primary supplier for institutional hygiene products. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates prompt action to quarantine affected stock and communicate with downstream customers to prevent further distribution. The core reason for this significant market action is a documented Current Good Manufacturing Practice (CGMP) deviation. Specifically, the KleenFoam Antimicrobial Foam Soap was produced at a facility where other products and lots were identified as contaminated. This raises critical questions for regulatory affairs heads regarding DermaRite’s overall quality management system and contamination control strategies. A CGMP deviation of this nature suggests systemic issues in manufacturing processes, environmental monitoring, or quality control, which could extend beyond the recalled product. For business development executives, this event highlights the inherent risks associated with relying on manufacturers with compromised quality systems, potentially impacting brand reputation and market access for products sourced from such facilities. The ongoing status of this recall means that the FDA’s scrutiny of DermaRite’s operations is likely to continue, demanding a comprehensive remediation plan from the company.
Operational Impact at DermaRite's North Bergen Facility and Business Implications
The recall directly implicates DermaRite Industries, LLC’s manufacturing operations in North Bergen, New Jersey. While specific details on the facility’s capacity or its full product portfolio are not publicly available within the provided intelligence, the fact that the KleenFoam Antimicrobial Foam Soap (Chloroxylenol 0.5%) was manufactured in an environment where other products experienced contamination points to a broader operational challenge. For procurement directors, this situation demands a thorough re-evaluation of DermaRite as a supplier. The risk of cross-contamination within a multi-product facility can lead to cascading recalls, impacting a wider range of products beyond the initial scope. This necessitates a review of supplier qualification processes, ensuring that manufacturers demonstrate robust segregation, cleaning validation, and environmental monitoring protocols, especially for antiseptic or hygiene products where microbial control is paramount. Regulatory affairs heads must recognize that a CGMP deviation leading to contamination is a severe finding, indicating a failure to adhere to fundamental quality standards. This can trigger heightened regulatory oversight, including potential inspections and demands for extensive corrective and preventive actions (CAPA). The commercial implications for DermaRite are substantial, including financial losses from returned products, remediation costs, and potential damage to its market standing. For business development executives, understanding the root cause of such contamination—whether it stems from raw materials, processing, or the manufacturing environment itself—is crucial for assessing the long-term viability and reliability of DermaRite as a partner or competitor. The event underscores the imperative for all chemical and life sciences companies to maintain impeccable manufacturing hygiene and quality control, as failures directly translate into significant business disruption and reputational harm.
Supply Chain Vulnerability: Implications for Healthcare and Institutional Buyers of Chloroxylenol 0.5%
The recall of KleenFoam Antimicrobial Foam Soap, a Chloroxylenol 0.5% product, exposes potential vulnerabilities for downstream users, particularly in healthcare, hospitality, and other institutional settings that rely on such antiseptic solutions. Chloroxylenol 0.5% is a widely used active ingredient in antimicrobial soaps, valued for its broad-spectrum antimicrobial activity. For supply chain VPs, this recall necessitates an immediate audit of all Chloroxylenol 0.5% based product inventories and supplier contracts. The 15,267 cartridges represent a significant volume, and their removal from the market could create localized or temporary supply gaps, especially if alternative qualified suppliers are not readily available or if the affected lots constitute a substantial portion of a buyer’s standing order. Proactive communication with end-users and a rapid assessment of alternative product availability are critical to maintaining operational continuity. Regulatory affairs heads should also consider the broader implications for product efficacy and patient safety. If a facility has systemic contamination issues, even products not directly recalled might be at risk, leading to questions about the overall quality assurance of all products originating from that site. This event serves as a stark reminder for procurement teams to diversify their supplier base for critical raw materials and finished products like Chloroxylenol 0.5% antimicrobial soaps. Over-reliance on a single manufacturer, particularly one experiencing CGMP deviations, can lead to significant operational disruptions and compliance risks. Business development executives should view this as an opportunity to assess market demand for high-quality, reliably sourced antimicrobial products and potentially position their own offerings as more secure alternatives, emphasizing robust quality control and supply chain resilience.
Navigating Supplier Risk: Absence of Named Alternatives for Chloroxylenol 0.5% Antimicrobial Soap
Our current intelligence, derived from the knowledge graph, does not identify specific alternative suppliers for Chloroxylenol 0.5% antimicrobial foam soap in the context of this DermaRite recall. This absence of readily available named alternatives underscores a critical challenge for procurement directors and supply chain VPs: the need for proactive supplier diversification and robust qualification programs. In situations where a primary supplier faces a significant regulatory action like a Class II recall due to CGMP deviations and contamination, the immediate lack of pre-qualified alternatives can lead to severe supply chain disruptions, increased costs, and potential operational halts for businesses reliant on these products. The qualification timeline for a new supplier, encompassing audits, sample testing, and regulatory documentation, can span several months, making rapid transitions difficult. Regulatory affairs heads must emphasize the importance of maintaining a portfolio of approved suppliers, even for seemingly commoditized products. This includes conducting thorough due diligence on potential secondary or tertiary suppliers, assessing their manufacturing capabilities, quality systems, and regulatory compliance history. For Chloroxylenol 0.5% products, which are often used in sensitive environments, the bar for quality and sterility assurance is particularly high. Business development executives should recognize that companies with strong, diversified supply chains and transparent quality control processes gain a significant competitive advantage. This incident reinforces the strategic imperative to invest in supply chain resilience, moving beyond single-source dependencies to mitigate the commercial and reputational risks associated with supplier quality failures.
Broader Industry Context: Recent Quality Control Challenges and Regulatory Scrutiny
The DermaRite Industries recall is not an isolated incident but rather reflects a broader trend of heightened regulatory scrutiny and persistent quality control challenges within the global chemical and life sciences industry. Our intelligence highlights recent parallel events that underscore these systemic pressures. For instance, Essential Wellness Pharma faced an FDA Class II recall for its Progesterone Injection in June 2026 due to sterility assurance failures. This event, similar in its Class II severity, demonstrates that manufacturing defects, particularly those related to contamination and quality control, remain a significant concern across different product types, from topical soaps to injectable pharmaceuticals. For regulatory affairs heads, these parallel events signal that the FDA is maintaining a vigilant stance on CGMP compliance and product quality, irrespective of the product’s therapeutic area or classification. Furthermore, the FDA’s ongoing hearing concerning Amgen’s Tavneos market future, also in June 2026, due to an independent data review, illustrates the agency’s willingness to challenge even established market players on data integrity and product efficacy. While distinct from a manufacturing recall, it points to a comprehensive regulatory environment where all aspects of a product’s lifecycle, from development to post-market surveillance, are under intense scrutiny. For business development executives, these trends emphasize the need for robust quality systems, not just to avoid recalls but to ensure long-term market access and competitive advantage. Procurement directors must recognize that supplier quality issues are a pervasive risk, requiring continuous monitoring and a proactive approach to risk management across their entire vendor portfolio, especially for critical raw materials and finished goods in the pharmaceutical and personal care sectors.
DermaRite's Path Forward: Remediation, Compliance, and Future Regulatory Scrutiny
With the Class II recall for KleenFoam Antimicrobial Foam Soap currently classified as "Ongoing" by the FDA, DermaRite Industries, LLC faces a critical period requiring immediate and comprehensive remediation. For regulatory affairs heads, this means DermaRite must conduct a thorough investigation into the root cause of the CGMP deviation and the contamination events. This will involve detailed analyses of their manufacturing processes, environmental controls, raw material quality, and quality management systems at the North Bergen, NJ facility. The company will be expected to implement robust corrective and preventive actions (CAPA) to address these deficiencies, which may include facility upgrades, process revalidation, enhanced training, and improved quality control procedures. The FDA will closely monitor DermaRite’s progress, potentially through follow-up inspections, to ensure the effectiveness of these actions. For procurement directors and supply chain VPs, the ongoing nature of this recall implies continued uncertainty regarding DermaRite’s long-term supply reliability for other products manufactured at the same facility. Companies sourcing from DermaRite should engage in direct communication to understand the scope of the remediation efforts and their timelines. Failure by DermaRite to adequately address the CGMP deviations could lead to further regulatory actions, such as an FDA Warning Letter, increased inspection frequency, or even an Import Alert if products were to be sourced internationally. Business development executives should anticipate that DermaRite’s market position and brand reputation will be under pressure until these quality issues are definitively resolved and verified by the FDA. This situation underscores the commercial imperative for swift and effective compliance resolution to restore market confidence and ensure business continuity.